Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut R Maecke

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2010
Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumorsMelpomeni Fani, Andreas Mueller, Maria-Luisa Tamma, et al.
Nuclear Medicine and Biology|March 6, 2019
Accuracy of [<sup>68</sup>Ga]Ga-RM2-PET/CT for diagnosis of primary prostate cancer compared to histopathologyThomas F Fassbender, Florian Schiller, Michael Mix, et al.
Plos One|April 19, 2018
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft modelSvetlana N Rylova, Christian Stoykow, Luigi Del Pozzo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 30, 2016
Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic TracersSvetlana N Rylova, Beatrice Waser, Luigi Del Pozzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targetingMihaela Ginj, Hanwen Zhang, Klaus-Peter Eisenwiener, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2011
First clinical evidence that imaging with somatostatin receptor antagonists is feasibleDamian Wild, Melpomeni Fani, Martin Behe, et al.
Clinical Nuclear Medicine|May 27, 2020
Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CTKerstin Michalski, Katharina Laubner, Christian Stoykow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumorsJürgen Grünberg, Ilse Novak-Hofer, Michael Honer, et al.
Cancer Research|January 20, 2011
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)Damian Wild, Michael Frischknecht, Hanwen Zhang, et al.
Cancer|March 13, 2009
[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trialFabienne Iten, Beat Muller, Christian Schindler, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2010
Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumorsMelpomeni Fani, Andreas Mueller, Maria-Luisa Tamma, et al.
Nuclear Medicine and Biology|March 6, 2019
Accuracy of [<sup>68</sup>Ga]Ga-RM2-PET/CT for diagnosis of primary prostate cancer compared to histopathologyThomas F Fassbender, Florian Schiller, Michael Mix, et al.
Plos One|April 19, 2018
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft modelSvetlana N Rylova, Christian Stoykow, Luigi Del Pozzo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 30, 2016
Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic TracersSvetlana N Rylova, Beatrice Waser, Luigi Del Pozzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targetingMihaela Ginj, Hanwen Zhang, Klaus-Peter Eisenwiener, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2011
First clinical evidence that imaging with somatostatin receptor antagonists is feasibleDamian Wild, Melpomeni Fani, Martin Behe, et al.
Clinical Nuclear Medicine|May 27, 2020
Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CTKerstin Michalski, Katharina Laubner, Christian Stoykow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumorsJürgen Grünberg, Ilse Novak-Hofer, Michael Honer, et al.
Cancer Research|January 20, 2011
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)Damian Wild, Michael Frischknecht, Hanwen Zhang, et al.
Cancer|March 13, 2009
[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trialFabienne Iten, Beat Muller, Christian Schindler, et al.
Pageof 9